TISIDB

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Endosome membrane Single-pass type I membrane protein
Domain	PF00028 Cadherin domain PF07714 Protein tyrosine kinase
Function	Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which induces inhibition of food-intake. Activates MAPK- and AKT-signaling pathways (PubMed:28846097, PubMed:28953886, PubMed:28846099). Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL (PubMed:28846099).

> Gene Ontology [ TOP ]
Biological Process	GO:0001101 response to acid chemical GO:0001654 eye development GO:0001655 urogenital system development GO:0001656 metanephros development GO:0001657 ureteric bud development GO:0001667 ameboidal-type cell migration GO:0001755 neural crest cell migration GO:0001822 kidney development GO:0001823 mesonephros development GO:0001838 embryonic epithelial tube formation GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007158 neuron cell-cell adhesion GO:0007259 JAK-STAT cascade GO:0007409 axonogenesis GO:0007423 sensory organ development GO:0007494 midgut development GO:0007497 posterior midgut development GO:0008361 regulation of cell size GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0014031 mesenchymal cell development GO:0014032 neural crest cell development GO:0014033 neural crest cell differentiation GO:0014041 regulation of neuron maturation GO:0014042 positive regulation of neuron maturation GO:0016331 morphogenesis of embryonic epithelium GO:0018105 peptidyl-serine phosphorylation GO:0018108 peptidyl-tyrosine phosphorylation GO:0018209 peptidyl-serine modification GO:0018212 peptidyl-tyrosine modification GO:0021675 nerve development GO:0021700 developmental maturation GO:0022604 regulation of cell morphogenesis GO:0030335 positive regulation of cell migration GO:0031346 positive regulation of cell projection organization GO:0032526 response to retinoic acid GO:0032535 regulation of cellular component size GO:0032835 glomerulus development GO:0033135 regulation of peptidyl-serine phosphorylation GO:0033136 serine phosphorylation of STAT3 protein GO:0033138 positive regulation of peptidyl-serine phosphorylation GO:0033139 regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033555 multicellular organismal response to stress GO:0033619 membrane protein proteolysis GO:0033627 cell adhesion mediated by integrin GO:0033628 regulation of cell adhesion mediated by integrin GO:0033630 positive regulation of cell adhesion mediated by integrin GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0035799 ureter maturation GO:0038034 signal transduction in absence of ligand GO:0040017 positive regulation of locomotion GO:0042493 response to drug GO:0042501 serine phosphorylation of STAT protein GO:0042551 neuron maturation GO:0043010 camera-type eye development GO:0045666 positive regulation of neuron differentiation GO:0045785 positive regulation of cell adhesion GO:0045793 positive regulation of cell size GO:0046425 regulation of JAK-STAT cascade GO:0048265 response to pain GO:0048469 cell maturation GO:0048483 autonomic nervous system development GO:0048484 enteric nervous system development GO:0048537 mucosal-associated lymphoid tissue development GO:0048541 Peyer's patch development GO:0048565 digestive tract development GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048762 mesenchymal cell differentiation GO:0048799 animal organ maturation GO:0048863 stem cell differentiation GO:0048864 stem cell development GO:0050769 positive regulation of neurogenesis GO:0050770 regulation of axonogenesis GO:0050900 leukocyte migration GO:0051272 positive regulation of cellular component movement GO:0051962 positive regulation of nervous system development GO:0055123 digestive system development GO:0060041 retina development in camera-type eye GO:0060384 innervation GO:0060485 mesenchyme development GO:0060562 epithelial tube morphogenesis GO:0061146 Peyer's patch morphogenesis GO:0061564 axon development GO:0071229 cellular response to acid chemical GO:0071300 cellular response to retinoic acid GO:0071396 cellular response to lipid GO:0071695 anatomical structure maturation GO:0072001 renal system development GO:0072006 nephron development GO:0072073 kidney epithelium development GO:0072163 mesonephric epithelium development GO:0072164 mesonephric tubule development GO:0072175 epithelial tube formation GO:0072189 ureter development GO:0072210 metanephric nephron development GO:0072215 regulation of metanephros development GO:0072216 positive regulation of metanephros development GO:0072224 metanephric glomerulus development GO:0072298 regulation of metanephric glomerulus development GO:0072300 positive regulation of metanephric glomerulus development GO:0072676 lymphocyte migration GO:0090066 regulation of anatomical structure size GO:0090183 regulation of kidney development GO:0090184 positive regulation of kidney development GO:0090192 regulation of glomerulus development GO:0090193 positive regulation of glomerulus development GO:0097021 lymphocyte migration into lymphoid organs GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:0097696 STAT cascade GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules GO:1903261 regulation of serine phosphorylation of STAT3 protein GO:1903263 positive regulation of serine phosphorylation of STAT3 protein GO:1903429 regulation of cell maturation GO:1903431 positive regulation of cell maturation GO:1904892 regulation of STAT cascade GO:2000147 positive regulation of cell motility GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001238 positive regulation of extrinsic apoptotic signaling pathway GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0019199 transmembrane receptor protein kinase activity
Cellular Component	GO:0005769 early endosome GO:0010008 endosome membrane GO:0030424 axon GO:0030425 dendrite GO:0043025 neuronal cell body GO:0043235 receptor complex GO:0044297 cell body GO:0044440 endosomal part GO:0045121 membrane raft GO:0098589 membrane region GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04144 Endocytosis
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-422475: Axon guidance R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04144 Endocytosis

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between RET and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between RET and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29631966	adenocarcinomas; squamous Cell Carcinoma	Inhibit immunity	The receptor tyrosine kinase MET is implicated in malignant transformation, tumor progression, metastasis, and acquired treatment resistance.
27994058	Thyroid Gland Carcinoma	Inhibit immunity	Conversely, RET/PTC3-expressing cells were characterized by a high IDO1 expression. These data provide the first evidence of a direct link between IDO1 expression and the oncogenic activation of RET in thyroid carcinoma and describe the involved signal transduction pathways.

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of RET in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of RET in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.224	0.315
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.188	0.68
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.249	0.515
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.014	0.977
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.063	0.962
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.111	0.945
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.203	0.701
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.582	0.457
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.176	0.833
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.045	0.921
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.457	0.489
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.195	0.313

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of RET in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	1.4	9.7	0.0589
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	1.7	9.4	0.0895
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	7.4	0.5	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RET. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RET. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RET. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RET. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of RET expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between RET and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	RET
Name	ret proto-oncogene
Aliases	CDHF12; RET51; CDHR16; cadherin-related family member 16; RET receptor tyrosine kinase; rearranged during tr ......
Chromosomal Location	10q11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting RET collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting RET.

ID	Name	Drug Type	Targets	#Targets
DB00398	Sorafenib	Small Molecule	BRAF, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	10
DB01809	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	Small Molecule	HCK, RET	2
DB05294	Vandetanib	Small Molecule	EGFR, PTK6, RET, TEK, VEGFA	5
DB08875	Cabozantinib	Small Molecule	KDR, MET, RET	3
DB08896	Regorafenib	Small Molecule	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, ......	18
DB08901	Ponatinib	Small Molecule	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......	15
DB12742	Amuvatinib	Small Molecule	FLT3, KIT, MET, PDGFRA, RAD51, RET	6

Browse RET